ODISEI
Organoid-based Discovery platform for Innovative Screening, Evaluation and Identification
Organoid-based drug efficacy and toxicity evaluation solution
ODISEI ONC
Oncology
ODISEI PET
Companion Animals
ODISEI VIR
Infectious Diseases
ODISEI NEP
Renal Diseases
ODISEIGUT
Nutraceuticals
ODISEI CNS
Brain Diseases
ODISEI SKIN
Cosmetics
ODISEI HEP
Liver Diseases
ODISEI Spatial
Spatial Biology
Overview
ODISEI Solution precisely predicts the efficacy of rapidly evolving new materials
Discrepancies between animal testing and human results
The rise of animal ethics and the spread of alternative methods to animal testing
Astronomical costs
involved
& Low success rates
Challenges in
evaluating new
modality drugs
Providing the optimal evaluation solution to accurately assess advanced pharmaceuticals and
new materials without animal testing, enhancing the efficiency of drug development
Advantages of Organoid Model
Experience more precise, easier, faster, and reliable drug efficacy evaluation ODISEI Solutions for your successful drug discovery.
Type
Similarity with
human organs
Physiological
complexity
Time for
Establishment
Success
rate Mass
production Ethical
issue
rate Mass
production Ethical
issue
3D Organoid
High
Relatively
complex
Weeks
High
Possible
No
2D Cells
(PDC)
Low
Simple
Days
High
Possible
No
PDX Model (PDX)
High
Complex
Months
Low
Impossible
Yes
Strategies: Basic Research
- Connecting genotypes to specific phenotypes
- Cancer initiation and progression
- Clonal evolution
- Cancer stem cell characterization
- Mechanism of drug response and resistance
Utilization Strategy for Each Stage of New Drug Development
Target Section
1. New target excavation and verification
Lead Finding,
Prioritization Optimization
2. New drug screening
3. Drug efficacy Evaluate and optimize
3. Drug efficacy Evaluate and optimize
Phase I
4. Clinical trial Prediction of success rate
Phase II
Phase III
5. Clinical trial protocol development
6. Treatment prediction marker development
Organoid Establishment and Banking
Over 20 diverse organoids, including TME (Tumor Microenvironment) , enabling cutting-edge trends like Neoantigen and Immunotherapy applications
- Skin & Hair
- Cerebral
- Midbrain
- Lacrimal Gland
- Salivary Gland
- Adenoid
- Tonsil
- Lung
- Heart
- Liver
- Stomach
- Kidney
- Intestine
- Prostate Cancer
- Hepatocellular Carcinoma
- Breast Cancer
- Pancreatic Cancer
- Renal Cell Carcinoma
- Endometrial Cancer
- Head & Neck Cancer
- Non-Small Cell Lung Cancer
- Cholangiocarcinoma
- Gastric Cancer
- Colorectal Cancer
- Ovarian Cancer
Available pre-clinical research
- Donor-matched immune microenvironment
- Various patient-derived organoid lineups
- High-resolution data
(HCS, FACS, NGS, scRNAseq, multiflex IHC) - Fully customized service
Available clinical data
- Basic clinical data
- Drug sensitivity prediction
- Patient follow-up data
- Clinical bioinformatics
(NGS, RNAseq, Spatial biology)
Applications
Find out how we can be your partner in providing ethical choices and exceptional results
Client
Therapeutic Approaches
- Antibodies
- Anti-Cancer Drugs
- Vaccines
- Small Molecules
- Peptides
- Nucleosides
- Microbiome
- Virus
- Cosmetic Compounds
- Proinflammatory-Cytokines
- Proinflammatory-Chemokines
Read-outs
- Morphology
- Cell viability
- Cell type composition
- Gene expression
- Mutation profiling
- Immune cell profiling
- Pathway analysis
- Cell to cell interaction
- Metabolism
Disease Modeling
- Oncology Virus
- Oncology Skin
- Oncology Gut
- Cytotoxic T Cells
- Macrophages
- DCs
- Tregs
- NKs
- CAFs
- Skin
- Intestinal
- Liver
- Kidney
- Cardiac
- Lung
- Stomach
- Brain
Analysis
- High-content Screening
- Cell Viability
- Fluorescence-sorting
- Fluorescence-activated Cell Sorting
- Confocal Microscopy
- Immunohistochemistry
- Immunofluorescence
- Phenocycler-fusion
- (Multiplex-IHC)
- -CODEX, OPAL
- Bulk-RNAseq
- Single Cell RNAseq
- Whole Genome Sequencing
- MS/MS
Report
ODISEI ONC
Precision oncology solution replicating patient tumors and immune microenvironments for anti-cancer and immunotherapy evaluation
High-Fidelity Preclinical Models
Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
Extensive Organoid Biobanking
A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.
ODISEI-ONC : 종양 오가노이드를 이용한 면역항암제 평가 플랫폼
ODISEI GUT
Precision oncology solution replicating patient tumors and immune microenvironments for anti-cancer and immunotherapy evaluation
High-Fidelity Preclinical Models
Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
Extensive Organoid Biobanking
A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.
ODISEI-ONC : 종양 오가노이드를 이용한 면역항암제 평가 플랫폼
ODISEI SKIN
Precision oncology solution replicating patient tumors and immune microenvironments for anti-cancer and immunotherapy evaluation
High-Fidelity Preclinical Models
Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
Extensive Organoid Biobanking
A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.
ODISEI-ONC : 종양 오가노이드를 이용한 면역항암제 평가 플랫폼
ODISEI Spatial
Precision oncology solution replicating patient tumors and immune microenvironments for anti-cancer and immunotherapy evaluation
High-Fidelity Preclinical Models
Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.
Extensive Organoid Biobanking
A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.
This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.
ODISEI-ONC : 종양 오가노이드를 이용한 면역항암제 평가 플랫폼
Features
Enhance clinical predictive accuracy by developing advanced
models that more accurately recapitulate the Tumor Microenvironment (TME)
Immune-Microenvironment with Cytoxic T cells
Immune checkpoint determine whether
cancer cells are killed after TCR-MHC binding
stablishment of an immune checkpoint blockade
evaluation platform utilizing cancer organoids and autologous T cells
Tumor-Infiltrating Lymphocyte (TIL)
Regulatory T cell (Treg)
Macrophage
Cancer Associate Fibroblast (CAF)
Validation Complete for caner organoid
- Clinical information
- Drug sensitivity test
- Genetic mutation (WES analysis)
- Specific cancer marker expression
(Immunohistochemistry, Multiflex)
WES analysis in pancreatic cancer organoid
Drug sensitivity test in pancreatic cancer organoid
Toward a Sustainable Future with ORGANOIDSCIENCES
Join ORGANOIDSCIENCES in leading groundbreaking organoid research and the advancement of next-generation cell therapies.
Be part of the journey of biomedical innovation that is shaping the future of healthcare.
Be part of the journey of biomedical innovation that is shaping the future of healthcare.
Technical Inquiry
bd@organoidrx.com
PR/Marketing inquiry
pr@organoidrx.com
Recruitment inquiry
hr.admin@organoidrx.com
General Inquiry
info@organoidrx.com